Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 29, 2012, Pages 11782-11787

  Liu, Wenhai ^a   Onda, Masanori ^a   Lee, Byungkook ^a   Kreitman, Robert J ^a   Hassan, Raffit ^a   Xiang, Laiman ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer treatment; Immunotherapy; Leukemia; Mesothelioma; Protein engineering

Indexed keywords

ALANINE; AMINO ACID DERIVATIVE; CD22 ANTIGEN; EPITOPE; IMMUNOTOXIN; NEUTRALIZING ANTIBODY; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; RECOMBINANT IMMUNOTOXIN HA22 LR LO10; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ALANINE SCANNING MUTAGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER CELL CULTURE; CANCER REGRESSION; CELL KILLING; DRUG CYTOTOXICITY; DRUG HALF LIFE; HUMAN; HUMAN CELL; HYDROPHILICITY; IMMUNOGENICITY; MOLECULAR LIBRARY; MOUSE; MUTAGENESIS; NONHUMAN; PHAGE DISPLAY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ENGINEERING; TREATMENT RESPONSE;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, B-LYMPHOCYTE; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS; NEOPLASMS; PEPTIDE LIBRARY; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; STATISTICS, NONPARAMETRIC;

MUS; PSEUDOMONAS EXOTOXIN;

EID: 84863957822     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1209292109     Document Type: Article

References (22)

1. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6:559-565. (Pubitemid 43980544)
2. FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I (2011) Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 71:6300-6309.
3. Kreitman RJ, Pastan I (2011) Antibody fusion proteins: Anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 17:6398-6405.
4. Kreitman RJ, et al. (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 30:1822-1828.
5. Wayne AS, et al. (2010) Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: Preclinical studies and phase I clinical trial. Clin Cancer Res 16:1894-1903.
6. Kreitman RJ, et al. (2000) Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18:1622-1636. (Pubitemid 30220540)
7. Hassan R, et al. (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13:5144-5149. (Pubitemid 47502082)
8. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I (2009) Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 15:5274-5279.
9. Onda M, et al. (2011) Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci USA 108:5742-5747.
10. Marks JD, et al. (1991) By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 222:581-597.
11. Marks JD, Tristem M, Karpas A, Winter G (1991) Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes. Eur J Immunol 21:985-991.
12. Benhar I, Reiter Y, Pai LH, Pastan I (1995) Administration of disulfide-stabilized Fvimmunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice. Int J Cancer 62:351-355.
13. Onda M, et al. (2006) Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 177:8822-8834. (Pubitemid 44893849)
14. Onda M, et al. (2008) An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 105:11311-11316.
15. Lee B, Richards FM (1971) The interpretation of protein structures: Estimation of static accessibility. J Mol Biol 55:379-400.
16. Kreitman RJ, Wang QC, FitzGerald DJP, Pastan I (1999) Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int J Cancer 81:148-155. (Pubitemid 29124210)
17. Weldon JE, et al. (2009) A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 113:3792-3800.
18. Miller JJ, Valdes R (1992) Methods for calculating cross-reactivity in immunoassays. J Clin Immunoassay 15:97-107.
19. Atassi MZ, et al. (1996) Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species. J Protein Chem 15:691-700.
20. Atassi MZ, Dolimbek BZ (2004) Mapping of the antibody-binding regions on the HNdomain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. Protein J 23:39-52. (Pubitemid 41399345)
21. Bang S, Nagata S, Onda M, Kreitman RJ, Pastan I (2005) HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 11:1545-1550. (Pubitemid 40315239)
22. Onda M, et al. (2005) New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res 11:5840-5846. (Pubitemid 41170311)